Upregulation of the PI3K/Akt Pathway in the Tumorigenesis of Canine Thyroid Carcinoma

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2014 Sep 19

PMID 25231196

Citations 18

Authors

M Campos

M M J Kool

S Daminet

R Ducatelle

G Rutteman

H S Kooistra

S Galac

J A Mol

Affiliations

Soon will be listed here.

Abstract

Background: Information on the genetic events leading to thyroid cancer in dogs is lacking.

Hypothesis/objectives: Upregulation of the PI3K/Akt pathway has an important role in the tumorigenesis of thyroid carcinoma in dogs.

Animals: Fifty-nine dogs with thyroid carcinoma and 10 healthy controls.

Methods: Quantitative RT-PCR was performed for VEGFR-1, VEGFR-2, EGFR, PIK3CA, PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2, and CALCA. Mutation analysis was performed for known hotspots of RAS (N, K, H), PIK3CA, BRAF, RET, and for the entire coding region of PTEN.

Results: Forty-three dogs (73%) had follicular cell thyroid carcinoma (FTC) and 16 dogs (27%) had medullary thyroid carcinoma (MTC). The relative mRNA expressions of VEGFR-1 (P < .001), VEGFR-2 (P = .002), PDPK1 (P < .001), AKT1 (P = .009), and AKT2 (P < .001) were increased in FTC, and those of EGFR (P < .001), VEGFR-1 (P = .036), and PIK3CA (P = .019) were increased in MTC when compared to normal thyroid glands. Mutation analysis of K-RAS identified 2 activating missense mutations, which also have been described in thyroid cancer of humans. A G12R substitution was present in 1 FTC and an E63K substitution was present in 1 MTC. No functional mutations were found in the sequenced regions of H-RAS, N-RAS, PIK3CA, BRAF, RET, and PTEN.

Conclusions And Clinical Importance: The increased expression of several genes associated with PI3K/Akt signaling suggests the involvement of this pathway in the pathogenesis of thyroid carcinoma in dogs, warranting further research on pathway activation and gene amplification. The mutations most frequently associated with thyroid cancer in humans are rare in dogs.

Citing Articles

Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma.

Nururrozi A, Igase M, Miyanishi K, Sakurai M, Sakai Y, Tanabe M In Vivo. 2024; 39(1):110-119.

PMID: 39740903 PMC: 11705126. DOI: 10.21873/invivo.13808.

A recurrent somatic missense mutation in GNAS gene identified in familial thyroid follicular cell carcinomas in German longhaired pointer dogs.

Yu Y, Manders F, Grinwis G, Groenen M, Crooijmans R BMC Genomics. 2022; 23(1):669.

PMID: 36151521 PMC: 9508735. DOI: 10.1186/s12864-022-08885-y.

Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate.

Ichimata M, Nishiyama S, Matsuyama F, Fukazawa E, Harada K, Katayama R J Vet Med Sci. 2021; 83(10):1554-1558.

PMID: 34408099 PMC: 8569883. DOI: 10.1292/jvms.21-0254.

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.

Musser M, Johannes C BMC Vet Res. 2021; 17(1):269.

PMID: 34380474 PMC: 8356392. DOI: 10.1186/s12917-021-02978-8.

Deleterious Mutations in the TPO Gene Associated with Familial Thyroid Follicular Cell Carcinoma in Dutch German Longhaired Pointers.

Yu Y, Bovenhuis H, Wu Z, Laport K, Groenen M, Crooijmans R Genes (Basel). 2021; 12(7).

PMID: 34209805 PMC: 8306087. DOI: 10.3390/genes12070997.

References

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

Lee J, Larsson C, Lui W, Hoog A, von Euler H . A dog pedigree with familial medullary thyroid cancer. Int J Oncol. 2006; 29(5):1173-82. View

Malumbres M, Barbacid M . RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3(6):459-65. DOI: 10.1038/nrc1097. View

Hong H, Houle C, Ton T, Sills R . K-ras mutations in lung tumors and tumors from other organs are consistent with a common mechanism of ethylene oxide tumorigenesis in the B6C3F1 mouse. Toxicol Pathol. 2007; 35(1):81-5. PMC: 2099306. DOI: 10.1080/01926230601063839. View

Quilliam L, Hisaka M, Zhong S, Lowry A, Mosteller R, Han J . Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. J Biol Chem. 1996; 271(19):11076-82. DOI: 10.1074/jbc.271.19.11076. View

Galac S, Kool M, Naan E, Daminet S, Mol J, Kooistra H . Expression of the ACTH receptor, steroidogenic acute regulatory protein, and steroidogenic enzymes in canine cortisol-secreting adrenocortical tumors. Domest Anim Endocrinol. 2010; 39(4):259-67. DOI: 10.1016/j.domaniend.2010.07.001. View

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S . Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012; 97(10):E2031-5. PMC: 3462939. DOI: 10.1210/jc.2012-2092. View

Fuhrer D, Eszlinger M, Karger S, Krause K, Engelhardt C, Hasenclever D . Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. Eur J Endocrinol. 2005; 152(5):785-90. DOI: 10.1530/eje.1.01912. View

Gerber H, McMurtrey A, Kowalski J, Yan M, Keyt B, Dixit V . Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998; 273(46):30336-43. DOI: 10.1074/jbc.273.46.30336. View

10.

Chen Y, Tan K, Pang L, Argyle D . The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res. 2012; 8:73. PMC: 3515332. DOI: 10.1186/1746-6148-8-73. View

11.

Liebner D, Shah M . Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2012; 2(5):173-95. PMC: 3474640. DOI: 10.1177/2042018811419889. View

12.

Ladu S, Calvisi D, Conner E, Farina M, Factor V, Thorgeirsson S . E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 2008; 135(4):1322-32. PMC: 2614075. DOI: 10.1053/j.gastro.2008.07.012. View

13.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

14.

Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T . PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res. 2001; 7(9):2636-42. View

15.

Scheffzek K, Ahmadian M, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F . The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997; 277(5324):333-8. DOI: 10.1126/science.277.5324.333. View

16.

Xing M . Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13(3):184-99. PMC: 3791171. DOI: 10.1038/nrc3431. View

17.

Salvatore D, Melillo R, Monaco C, Visconti R, Fenzi G, Vecchio G . Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res. 2001; 61(4):1426-31. View

18.

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

19.

Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry J, De Micco C . Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003; 88(6):2745-52. DOI: 10.1210/jc.2002-021186. View

20.

Chen W, Bai L, Wang X, Xu S, Belinsky S, Lin Y . Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol. 2009; 77(3):416-23. PMC: 2835422. DOI: 10.1124/mol.109.061226. View